The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

The FDA sent out "100 cease-and-desist letters" to brands in response to what it says is "deceptive" pharma advertising - which could massively impact pharma's $7 billion U.S. national TV ad ...

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

The Chinese biotech will now pursue the further development of ASC30 in obesity for use as a maintenance and treatment ...

Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

After struggling to find relief, GLP-1s were the "miracle solution" to their PCOS symptoms. But without insurance coverage, many can't afford them.

The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9,000 positions to streamline ...

In response to what it says is "deceptive" pharmaceutical ads, the FDA sent out "100 cease-and-desist letters" to brands - a move that could have massive impact on pharma's $7 billion U.S. national TV ...

Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...

Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular ...